anrukinzumab (IMA-638) / Pfizer - LARVOL DELTA

Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review. (PubMed, J Asthma Allergy) - "Omalizumab reduced AHR to methacholine, acetylcholine or adenosine monophosphate (3/9 studies), and reduced EAR (4/5 studies) and LAR (2/3 studies). Mepolizumab had no effect on AHR (3/3 studies), EAR or LAR (1/1 study)...Pitrakinra reduced LAR, with no effect on AHR (1/1 study). Etanercept reduced AHR to methacholine (1/2 studies). No effects were observed for lebrikizumab, tocilizumab, efalizumab, IMA-638 and anti-OX40 ligand on AHR, EAR or LAR; benralizumab on LAR; tralokinumab on AHR; and Ro-24-7472 on AHR or LAR (all 1/1 study each). No dupilumab or reslizumab studies were identified...These findings provide insights into AHR mechanisms and the precise effects of asthma biologics. Furthermore, findings suggest that tezepelumab broadly targets allergen-specific and non-allergic forms of AHR, and the underlying cells and mediators involved in asthma."

Journal • Review • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study. (PubMed, Front Immunol) - "The search strategies were as follows: topic: TS=(biologic* OR "biologic* product*" OR "biologic* therap*" OR biotherapy* OR "biologic* agent*" OR Benralizumab OR "MEDI-563" OR Fasenra OR "BIW-8405" OR Dupilumab OR SAR231893 OR "SAR-231893" OR Dupixent OR REGN668 OR "REGN-668" OR Mepolizumab OR Bosatria OR "SB-240563" OR SB240563 OR Nucala OR Omalizumab OR Xolair OR Reslizumab OR "SCH-55700" OR SCH55700 OR "CEP-38072" OR CEP38072 OR Cinqair OR "DCP-835" OR DCP835 OR Tezspire OR "tezepelumab-ekko" OR "AMG-157" OR tezspire OR "MEDI-9929" OR "MEDI-19929" OR MEDI9929 OR Itepekimab OR "REGN-3500"OR REGN3500 OR "SAR-440340"OR SAR440340 OR Tralokinumab OR "CAT-354" OR Anrukinzumab OR "IMA-638" OR Lebrikizumab OR "RO-5490255"OR "RG-3637"OR "TNX-650"OR..."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Effect of Biologics on Allergic Response and Airway Hyperresponsiveness: A Systematic Literature Review (ATS 2022) - "Mepolizumab had no effect on EAR or LAR (1/1 study) or AHR (3/3 studies). In one study each, IMA-638, lebrikizumab and tralokinumab had no effect on AHR. Pitrakinra reduced LAR, with no effect on AHR (1/1 study). Etanercept reduced AHR in one study. Benralizumab had no effect on LAR (1/1 study), and no studies were identified assessing AHR. In one study each, efalizumab, tocilizumab, Ro-24-7472 and anti-OX40 ligand had no effect on AHR...No published studies were identified for dupilumab or reslizumab.CONCLUSIONSAcross multiple biologics studied, reductions in both EAR and LAR to allergens were observed with omalizumab and tezepelumab. Tezepelumab also consistently attenuated nonspecific AHR to methacholine or mannitol. These findings provide further insight into the mechanisms of AHR and the clinical benefits of asthma biologics and suggest that tezepelumab may broadly target mediators or cells involved in asthma inflammation."

Review • Allergy • Asthma • Inflammation • Pulmonary Disease • Respiratory Diseases

Pfizer pipeline (Pfizer Press Release) - Anrukinzumab: Discontinued from development for ulcerative colitis.

Discontinued • Immunology • Inflammatory Bowel Disease

The role of interleukin-13 in chronic inflammatory intestinal disorders. (PubMed, Autoimmun Rev) - "Failure of the anti-IL-13 monoclonal antibodies tralokinumab and anrukinzumab in UC patients in clinical trials support the absence of a role for IL-13 in UC. This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool."

Journal • Review